Enodia Therapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $24.3M

  • Investors
  • 10

Enodia Therapeutics General Information

Description

Operator of a biotechnology research company intended to focus on the discovery and development of treatments for neurodegenerative diseases. The company operates at the translational stage of research, bridging academic science and industrial drug development by advancing therapeutic concepts through preclinical validation and optimization and lead compounds, and prepares candidates for clinical evaluation, enabling clients to transform early scientific findings into viable therapeutic services.

Contact Information

Website
www.enodiatx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 26 rue Bosquet
  • 75007 Paris
  • France
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 26 rue Bosquet
  • 75007 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enodia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Seed Round 08-Jan-2026 $24.3M Completed Startup
4. Accelerator/Incubator 01-Jan-2025 Completed Startup
3. Accelerator/Incubator 01-Jan-2025 Completed Startup
2. Accelerator/Incubator 01-Jan-2025 Completed Startup
1. Spin-Off 01-Jan-2025 Completed Startup
To view Enodia Therapeutics’s complete valuation and funding history, request access »

Enodia Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Enodia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4486451-A1 Sec61 inhibitors and use thereof Pending 28-Feb-2022
US-20250171434-A1 Sec61 inhibitors and use thereof Pending 28-Feb-2022
US-20230286973-A1 Protein secretion inhibitors Pending 31-Aug-2020
US-20220153732-A1 Protein secretion inhibitors Pending 28-Feb-2019
US-11339193-B2 Cdp protein secretion inhibitors Active 29-Mar-2018 C07K11/02
To view Enodia Therapeutics’s complete patent history, request access »

Enodia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enodia Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund Minority
Carbon ( Belgium ) Venture Capital Minority
Elaia Partners Venture Capital Minority
Groupe MACSF Venture Capital Minority
Mission BioCapital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Enodia Therapeutics Investments (1)

Enodia Therapeutics’s most recent deal was a Corporate Asset Purchase with Kezar Life Sciences (Preclinical Assets) for . The deal was made on 06-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kezar Life Sciences (Preclinical Assets) 06-Mar-2026 Corporate Asset Purchase Buildings and Property
To view Enodia Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial

Enodia Therapeutics FAQs

  • When was Enodia Therapeutics founded?

    Enodia Therapeutics was founded in 2025.

  • Where is Enodia Therapeutics headquartered?

    Enodia Therapeutics is headquartered in Paris, France.

  • What is the size of Enodia Therapeutics?

    Enodia Therapeutics has 1 total employees.

  • What industry is Enodia Therapeutics in?

    Enodia Therapeutics’s primary industry is Biotechnology.

  • Is Enodia Therapeutics a private or public company?

    Enodia Therapeutics is a Private company.

  • What is the current valuation of Enodia Therapeutics?

    The current valuation of Enodia Therapeutics is .

  • What is Enodia Therapeutics’s current revenue?

    The current revenue for Enodia Therapeutics is .

  • How much funding has Enodia Therapeutics raised over time?

    Enodia Therapeutics has raised $24.3M.

  • Who are Enodia Therapeutics’s investors?

    Bpifrance, Carbon ( Belgium ), Elaia Partners, Groupe MACSF, and Mission BioCapital are 5 of 10 investors who have invested in Enodia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process